Tag
This article examines the critical need for refined clinical metrics in thyroid eye disease (TED) to better evaluate new targeted therapies, highlighting the Innovate TED Initiative’s efforts to develop and validate comprehensive outcome me
Phase 3 trials show satralizumab significantly improves proptosis, inflammation, and diplopia in thyroid eye disease with a favorable safety profile, marking a new therapeutic option targeting the IL-6 receptor pathway.
This study evaluates teprotumumab’s effectiveness for thyroid eye disease in Japanese patients, revealing notable improvements in orbital inflammation and proptosis compared to intravenous glucocorticoid therapy with distinct MRI-base
Stimulating TSH receptor antibodies enhance expression of TSHR and IGF-1R in fibroblasts via receptor recycling, elucidating mechanisms underlying thyroid eye disease and identifying potential therapeutic targets.
In phase 3 testing, veligrotug produced rapid and clinically meaningful reductions in proptosis, diplopia, and disease activity in active thyroid eye disease, with durable benefit through 52 weeks and a favorable short-term safety profile.
In two prospective cohorts of active, glucocorticoid-resistant thyroid eye disease, tocilizumab improved eye inflammation, proptosis, diplopia, and quality of life with acceptable safety, supporting IL-6 blockade as a promising second-line
A large multinational cohort study found that teprotumumab use in thyroid eye disease was associated with higher risks of prediabetes, diabetes, and antidiabetes medication initiation over 5 years.
The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.
Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.
